Agilent Technologies Stock News

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here to read this week's edition.

Agilent looks fundamentally undervalued after losing 30% since its ATH. The company delivers consistently solid financial results and is forecasted to further increase its profitability.

Agilent Technologies, AMETEK, Fortive, and Cognex Zacks Industry Outlook article.

Coronavirus--led disruptions are hurting the Zacks Electronics - Testing Equipment industry. However, industry participants like A, AME, FTV and CGNX are set to gain from 5G prospects.

Coronavirus--led disruptions are hurting the Zacks Electronics - Testing Equipment industry. However, industry participants like A, AME, FTV and CGNX are set to gain from 5G prospects.

Agilent Technologies (A) boosts its presence in the companion diagnostics market by expanding the use of PD-L1 IHC 28-8 pharmDx assay for esophageal squamous cell carcinoma treatment in the EU.

Agilent Technologies (A) boosts its presence in the companion diagnostics market by expanding the use of PD-L1 IHC 28-8 pharmDx assay for esophageal squamous cell carcinoma treatment in the EU.

The FIW ETF: Because Water Is More Essential Than Oil (Or Data)

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Russia's ongoing war with Ukraine is among the reasons that oil prices are soaring this year. Those high prices and geopolitical tensions are reminders that, for many nations, energy security is an es

Dallas, March 11, 2022 (GLOBE NEWSWIRE) -- As per the report published by The Brainy Insights, the global inflammatory bowel disease treatment market is expected to grow from USD 18.47 billion in 2020 to USD 28.96 billion by 2030, at a CAGR of 4.6% during the forecast period 2021-2030. Inflammatory bowel disease (IBD) is a term for illnesses involving chronic inflammation of the digestive tract. Some common symptoms of IBD are: abdominal pain, weight loss, persistent diarrhea, rectal bleeding and fatigue. Ulcerative colitis and Crohn''s disease are the two most common kinds of IBD. The colon or large intestine are the only parts of the body affected by ulcerative colitis. On the other hand, Crohn''s disease can affect any portion of the gastrointestinal tract, from the mouth to the anus. The last part of the small intestine or the colon, or both, are the most usually affected areas. Anti-inflammatory drugs are frequently used as the first line of treatment against inflammatory bowel disease.

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.